Quantitative analysis method of extremely-low-concentration fluperidinol in blood plasma
A technology for quantitative analysis of haloperidol, which is applied in the direction of analysis materials, measuring devices, material separation, etc., can solve the problem of inability to evaluate drug absorption, distribution, metabolism, and excretion, and accurately quantify the blood concentration of haloperidol absorbed, Unable to guarantee the accuracy of clinical trials and other issues, to achieve good accuracy, strong anti-interference ability, and high sensitivity
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0033] 1. Sample pretreatment
[0034] Take 50 μL of plasma sample in a 96-well plate, add 50 μL of haloperidol-d4 internal standard solution with a concentration of 200 ng / mL to the plasma sample, add 400 μL of acetonitrile solution containing 0.05-0.3% formic acid by volume, and vortex to mix After centrifugation; pipette 200 μL supernatant to a new 96-well plate, add 200 μL aqueous solution containing 0.05-0.3% formic acid by volume, seal the plate, vortex and then centrifuge, take supernatant and inject; plasma sample to be tested K 2 Plasma separated by EDTA anticoagulation was stored in a -70°C ultra-low temperature freezer;
[0035] 2. Standard curve creation
[0036] Prepare the standard working solution with the haloperidol standard product, use the standard working solution and the blank plasma added with human K2EDTA to prepare the standard curve sample, and inject the sample after the pretreatment method in step (1), with the analyte concentration as the abscissa...
Embodiment 2
[0052] With above-mentioned embodiment 1, its difference is: chromatographic condition: chromatographic column adopts C18 chromatographic column, mobile phase A and B are the mixed solution of formic acid, acetonitrile and water, and the volume ratio of acetonitrile and water in mobile phase A is 2: 98 , the amount containing formic acid is 0.1% of the total volume of the solution; the volume ratio of acetonitrile and water in mobile phase B is 98:2, and the amount containing formic acid is 0.05% of the total volume of the solution; the gradient elution procedure is as follows: 0-0.3min , the proportion of mobile phase B is 25%; 0.30-2.10min, the proportion of mobile phase B is gradually changed from 25% to 98%; 2.10-2.50min, the proportion of mobile phase B is maintained at 98%; 2.50-2.51min, the proportion of mobile phase B is 98 % gradually changed to 25%; 2.51-3.00min, the proportion of mobile phase B was maintained at 25%; the injection volume was 10μL, the flow rate was 0...
Embodiment 3
[0054] With above-mentioned embodiment 1, its difference is: chromatographic condition: chromatographic column adopts C18 chromatographic column, mobile phase A and B are the mixed solution of formic acid, acetonitrile and water, and the volume ratio of acetonitrile and water in mobile phase A is 8: 92 , the amount containing formic acid is 0.25% of the total volume of the solution; the volume ratio of acetonitrile and water in mobile phase B is 92:8, and the amount containing formic acid is 0.25% of the total volume of the solution; the gradient elution procedure is as follows: 0-0.3min , the proportion of mobile phase B is 25%; 0.30-2.10min, the proportion of mobile phase B is gradually changed from 25% to 98%; 2.10-2.50min, the proportion of mobile phase B is maintained at 98%; 2.50-2.51min, the proportion of mobile phase B is 98 % gradually changed to 25%; 2.51-3.00min, the proportion of mobile phase B was maintained at 25%; the injection volume was 2μL, the flow rate was 0...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More